Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances

Journal of Psychiatric Research

Volumn 54, Issue 1, 2014, Pages 36-42

  Kao, A C C ^a,b   Rojnic Kuzman, M ^c   Tiwari, A K ^a,b   Zivkovic, M V ^f   Chowdhury, N I ^a   Medved, V ^c   Kekin, I ^c   Zai, C C ^a,b   Lieberman, J A ^d   Meltzer, H Y ^e   Bozina, T ^c   Bozina, N ^c   Kennedy, J L ^a,b   Sertic, J ^c   Muller D J ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF ZAGREB   (Croatia)

^d New York Presbyterian Columbia University Medical Center   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f Referentni centar za Alzheimerovu bolest i psihijatriju sta rijeivo t ne dobi   (Croatia)

Author keywords

A1298C; Antipsychotic; C677T; MTHFR; Weight gain

Indexed keywords

CLOZAPINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METHYLENETETRAHYDROFOLATE DEHYDROGENASE; NEUROLEPTIC AGENT; OLANZAPINE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

ALLELE; ARTICLE; CHOLESTEROL BLOOD LEVEL; FOLATE METABOLISM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; METABOLIC DISORDER; PRIORITY JOURNAL; PSYCHOSIS; WEIGHT GAIN; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; GENETICS; GENOTYPE; MALE; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; YOUNG ADULT;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; FEMALE; GENOTYPE; HUMANS; MALE; METABOLIC DISEASES; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; WEIGHT GAIN; YOUNG ADULT;

EID: 84899933130     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2014.03.012     Document Type: Article

References (39)

1. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21(2):263-265.
2. Basile V.S., Masellis M., De Luca V., Meltzer H.Y., Kennedy J.L. 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. Lancet 2002, 360(9347):1790-1791.
3. Bogolub C. Elevated homocysteine? Consider testing for folate metabolism gene variants. Minnesota Medicine 2012, 95(12):39-42.
4. Burghardt K.J., Ellingrod V.L. Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy: is there a role for folate?. Molecular Diagnosis & Therapy 2013, 17(1):21-30.
5. Devlin A.M., Ngai Y.F., Ronsley R., Panagiotopoulos C. Cardiometabolic risk and the MTHFR C677T variant in children treated with second-generation antipsychotics. Translational Psychiatry 2012, 2:e71.
6. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genetic Epidemiology 2003, 25(2):115-121.
7. Ellingrod V.L., Miller D.D., Taylor S.F., Moline J., Holman T., Kerr J. Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophrenia Research 2008, 98(1-3):47-54.
8. Ellingrod V.L., Taylor S.F., Dalack G., Grove T.B., Bly M.J., Brook R.D., et al. Risk factors associated with metabolic syndrome in bipolar and schizophrenia subjects treated with antipsychotics: the role of folate pharmacogenetics. Journal of Clinical Psychopharmacology 2012, 32(2):261-265.
9. Fodinger M., Wagner O.F., Horl W.H., Sunder-Plassmann G. Recent insights into the molecular genetics of the homocysteine metabolism. Kidney International Supplement 2001, 78:S238-S242.
10. Garcia-Miss Mdel R., Perez-Mutul J., Lopez-Canul B., Solis-Rodriguez F., Puga-Machado L., Oxte-Cabrera A., et al. Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia. Journal of Psychiatric Research 2010, 44(7):441-446.
11. Gauderman W.J. Sample size requirements for association studies of gene-gene interaction. American Journal of Epidemiology 2002, 155(5):478-484.
12. Gebhardt S., Theisen F.M., Haberhausen M., Heinzel-Gutenbrunner M., Wehmeier P.M., Krieg J.C., et al. Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study. Journal of Clinical Pharmacy and Therapeutics 2010, 35(2):207-211.
13. Klerk M., Verhoef P., Clarke R., Blom H.J., Kok F.J., Schouten E.G. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA: The Journal of the American Medical Association 2002, 288(16):2023-2031.
14. Kuzman M.R., Müller D.J. Association of the MTHFR gene with antipsychotic-induced metabolic abnormalities in patients with schizophrenia. Pharmacogenomics 2012, 13(8):843-846.
15. Lahiri D.K., Nurnberger J.I. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Research 1991, 19(19):5444.
16. Lee A.K., Bishop J.R. Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications. Pharmacogenomics 2011, 12(7):999-1016.
17. Lencz T., Malhotra A.K. Pharmacogenetics of antipsychotic-induced side effects. Dialogues in Clinical Neuroscience 2009, 11(4):405-415.
18. Lett T.A., Wallace T.J., Chowdhury N.I., Tiwari A.K., Kennedy J.L., Müller D.J. Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Molecular Psychiatry 2012, 17(3):242-266.
19. Levine J., Stahl Z., Sela B.A., Ruderman V., Shumaico O., Babushkin I., et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biological Psychiatry 2006, 60(3):265-269.
20. Lin P.I., Vance J.M., Pericak-Vance M.A., Martin E.R. No gene is an island: the flip-flop phenomenon. American Journal of Human Genetics 2007, 80(3):531-538.
21. Martin Y.N., Salavaggione O.E., Eckloff B.W., Wieben E.D., Schaid D.J., Weinshilboum R.M. Human methylenetetrahydrofolate reductase pharmacogenomics: gene resequencing and functional genomics. Pharmacogenetics and Genomics 2006, 16(4):265-277.
22. Masellis M., Basile V., Meltzer H.Y., Lieberman J.A., Sevy S., Macciardi F.M., et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998, 19(2):123-132.
23. Medved V., Kuzman M.R., Jovanovic N., Grubisin J., Kuzman T. Metabolic syndrome in female patients with schizophrenia treated with second generation antipsychotics: a 3-month follow-up. Journal of Psychopharmacology 2009, 23(8):915-922.
24. Müller D.J., Kennedy J.L. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 2006, 7(6):863-887.
25. Müller D.J., Klempan T.A., De Luca V., Sicard T., Volavka J., Czobor P., et al. The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neuroscience Letters 2005, 379(2):81-89.
26. Müller D.J., Muglia P., Fortune T., Kennedy J.L. Pharmacogenetics of antipsychotic-induced weight gain. Pharmacological Research: The Official Journal of the Italian Pharmacological Society 2004, 49(4):309-329.
27. Muntjewerff J.W., Kahn R.S., Blom H.J., den Heijer M. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Molecular Psychiatry 2006, 11(2):143-149.
28. Reed M.C., Nijhout H.F., Neuhouser M.L., Gregory J.F., Shane B., James S.J., et al. A mathematical model gives insights into nutritional and genetic aspects of folate-mediated one-carbon metabolism. The Journal of Nutrition 2006, 136(10):2653-2661.
29. Refsum H., Ueland P.M., Nygard O., Vollset S.E. Homocysteine and cardiovascular disease. Annual Review of Medicine 1998, 49:31-62.
30. Theisen F.M., Gebhardt S., Haberhausen M., Heinzel-Gutenbrunner M., Wehmeier P.M., Krieg J.C., et al. Clozapine-induced weight gain: a study in monozygotic twins and same-sex sib pairs. Psychiatric Genetics 2005, 15(4):285-289.
31. Tiwari A.K., Zai C.C., Likhodi O., Lisker A., Singh D., Souza R.P., et al. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia. Neuropsychopharmacology 2010, 35(6):1315-1324.
32. Trimmer E.E. Methylenetetrahydrofolate reductase: biochemical characterization and medical significance. Current Pharmaceutical Design 2013, 19(14):2574-2593.
33. van Winkel R., Moons T., Peerbooms O., Rutten B., Peuskens J., Claes S., et al. MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study. International Clinical Psychopharmacology 2010, 25(5):270-276.
34. van Winkel R., Rutten B.P., Peerbooms O., Peuskens J., van Os J., De Hert M. MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophrenia Research 2010, 121(1-3):193-198.
35. Volavka J., Czobor P., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J.P., et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. The American Journal of Psychiatry 2002, 159(2):255-262.
36. Wallace T.J., Zai C.C., Brandl E.J., Muller D.J. Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain. Pharmacogenomics and Personalized Medicine 2011, 4:83-93.
37. Wehmeier P.M., Gebhardt S., Schmidtke J., Remschmidt H., Hebebrand J., Theisen F.M. Clozapine: weight gain in a pair of monozygotic twins concordant for schizophrenia and mild mental retardation. Psychiatry Research 2005, 133(2-3):273-276.
38. Weiden P.J., Mackell J.A., McDonnell D.D. Obesity as a risk factor for antipsychotic noncompliance. Schizophrenia Research 2004, 66(1):51-57.
39. Wirshing D.A. Schizophrenia and obesity: impact of antipsychotic medications. The Journal of Clinical Psychiatry 2004, 65(Suppl. 18):13-26.